Tolerx

Tolerx, Inc.
Company typePrivate
IndustryBiotechnology
Founded2000
HeadquartersCambridge, Massachusetts
Websitehttp://www.tolerx.com/

Tolerx, Inc. was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases after a short course of therapy. Targeted diseases include type 1 diabetes, rheumatoid arthritis, Inflammatory bowel disease (IBD), cancer, chronic and viral diseases. In 2008, Tolerx was named one of Fierce Biotech’s Fierce 15.[1] In October 2011, Tolerx was shut down due to an unsuccessful Phase III trial in patients recently diagnosed with Type 1 diabetes.[2]

  1. ^ Fierce Biotech’s 2008 Fierce 15
  2. ^ "Exclusive: Tolerx cuts staff, auctioning assets after PhIII failure".
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.